Research / IVDA / Fundamental state Inspectable configuration
State dimensions Filing 0001493152-26-038440 General Corporate
Debt relative to revenue 89th Own-history percentile · N=18
Evidence method Level · gp.fundamentals.debt_to_revenue
79.76% · OPTIONAL · VALID
Operating cash generation 20th Own-history percentile · N=20
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-179.25% · OPTIONAL · VALID
Revenue growth 7th Own-history percentile · N=15
Evidence method Yoy · gp.fundamentals.revenue
-47.52% · CORE · VALID
Inventory pressure 55th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.inventory_revenue_ratio
30.26% · OPTIONAL · VALID
Gross margin 90th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.gross_margin
54.69% · CORE · VALID
Operating margin 35th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.operating_margin
-88.56% · CORE · VALID
R&D intensity RAW Current state valid · history insufficient
Evidence method Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
12.19% · OPTIONAL · NOT_ENOUGH_HISTORY
SBC intensity 40th Own-history percentile · N=15
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
1.50% · OPTIONAL · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 24 states Self-history eligible
Dec 31, 2021 0/7 normalized Level 3 Mar 31, 2022 0/7 normalized Level 3 Jun 30, 2022 0/7 normalized Level 3 Sep 30, 2022 0/8 normalized Level 3 Dec 31, 2022 3/8 normalized Level 3 Mar 31, 2023 6/8 normalized Level 3 Jun 30, 2023 4/6 normalized Level 3 Sep 30, 2023 5/6 normalized Level 3 Dec 31, 2023 6/7 normalized Level 3 Mar 31, 2024 6/7 normalized Level 3 Jun 30, 2024 7/8 normalized Level 3 Sep 30, 2024 8/8 normalized Level 3 Dec 31, 2024 8/9 normalized Level 3 Mar 31, 2025 6/7 normalized Level 3 Dec 31, 2024 7/8 normalized Amended as filed Jun 30, 2025 6/7 normalized Level 3 Sep 30, 2025 6/7 normalized Level 3 Dec 31, 2025 7/8 normalized Level 3 Mar 31, 2026 7/8 normalized Level 3 Jun 30, 2026 7/8 normalized Level 4 Period transition
What moved in the state? Balance Sheet Leverage Increased
Previous 23.74%
Current 79.76%
Delta 56.02% Cash Generation Decreased
Previous -62.05%
Current -179.25%
Delta -117.20% Growth Decreased
Previous 1.33%
Current -47.52%
Delta -48.85% Inventory Pressure Increased
Previous 16.60%
Current 30.26%
Delta 13.66% Margin Increased
Previous 33.14%
Current 54.69%
Delta 21.55% Profitability Decreased
Previous -37.86%
Current -88.56%
Delta -50.70% R And D Intensity Increased
Previous 2.01%
Current 12.19%
Delta 10.19% Sbc Intensity Increased
Previous 0.80%
Current 1.50%
Delta 0.69% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Mar 31, 2024
Similarity 76%
Compared 5 dimensions
Coverage 71% Margin 5.4 · Profitability 35.0 · Cash Generation 11.7 · Inventory Pressure 37.3 · Balance Sheet Leverage 11.1 Jun 30, 2025
Similarity 75%
Compared 6 dimensions
Coverage 86% Growth 29.7 · Margin 17.8 · Profitability 42.8 · Cash Generation 15.3 · Inventory Pressure 10.6 · Balance Sheet Leverage 17.5 Mar 31, 2026
Similarity 73%
Compared 7 dimensions
Coverage 100% Growth 43.3 · Margin 10.0 · Profitability 35.0 · Sbc Intensity 11.4 · Cash Generation 35.0 · Inventory Pressure 20.0 · Balance Sheet Leverage 18.3 Sep 30, 2024
Similarity 53%
Compared 7 dimensions
Coverage 100% Growth 55.8 · Margin 70.0 · Profitability 58.3 · Sbc Intensity 21.8 · Cash Generation 51.4 · Inventory Pressure 11.7 · Balance Sheet Leverage 25.3 Mar 31, 2023
Similarity 38%
Compared 6 dimensions
Coverage 86% Margin 67.8 · Profitability 65.0 · Sbc Intensity 27.5 · Cash Generation 80.0 · Inventory Pressure 32.8 · Balance Sheet Leverage 76.4 Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.